Print  |  Close

Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Active: Yes
Cancer Type: Graft Versus Host Disease NCT ID: NCT05544032
Trial Phases: Protocol IDs: INCA 34176-MA-GD-301 (primary)
Eligibility: 6 Years and older (Child, Adult, Older Adult ), Male and Female Study Type:
Study Sponsor: Incyte Corporation Medical Information Call Center (US)
NCI Full Details:

Summary

To provide axatilimab through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for axatilimab in the treatment of GVHD.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523


**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.